While early phase II and III trials have shown that adding anti-angiogenic agents to first-line EGFR TKIs in untreated EGFR-mutated NSCLC patients improves PFS, there was no significant improvement in OS. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.